Comparative trial of the effects of continuous locomotion training provided at pharmacies: a pilot study

Chigusa Kikuchi1,2*, Kyoko Yamaguchi2, Masayo Kojima3, Haruyuki Asai4, Rika Nakao5, Yoshifusa Otake6, Junya Nagata7, Shinpei Matsunami8, Asako Horiba9 and Tadashi Suzuki1,2

Abstract

Background: While the world’s population is growing older, healthy life expectancy is not increasing. The Japanese Orthopedic Association proposed the concept of ‘locomotive syndrome,’ manifested as a decline in mobility functions, and introduced a short test battery for assessing the risk of this syndrome. The test battery includes the ‘stand-up test,’ ‘two-step test,’ and ‘25-question Geriatric Locomotive Function Scale’ (25-question GLFS). The purpose of locomotion training is to improve and sustain standing and gait functions. However, the place where locomotion training can be provided and followed up has not been decided upon. Therefore, a study was conducted to explore the effect of locomotive syndrome improvement by continuous locomotion training provided at community pharmacies. The objective of this study was to evaluate the effect of pharmacists’ instructions and follow-up on the compliance and effectiveness of locomotion training.

Methods: The inclusion criteria were 1) age ≥65 years and 2) decline in mobility functions. Guidance on how to perform locomotion training was provided by a pharmacist at the pharmacy. The participants performed locomotion training at home. They were tested and instructed at the pharmacy once a month for 3 months. The main outcome measures were test battery results and the percentage of number of days participants who were able to do the training at home.

Results: Eleven participants were analysed. The minimum implementation percentage was 78%. Improvements were observed in 25-question GLFS, muscle strength, and standing time on one leg. Three participants no longer showed a noticeable decline in mobility function.

Conclusion: Continuous locomotion training provided at pharmacies could contribute to locomotive syndrome prevention.

Trial registration: This study was registered with the University hospital Medical Information Network Clinical Trials Registry (UMIN-CTR; identification No. UMIN000027963. Registered 28 June 2017).

Keywords: Pharmacy, Elderly, Locomotive syndrome, Locomotion training, Community, Health support
Background

The world’s elderly population is growing at an unprecedented rate. This phenomenon is considerably more pronounced in the Japanese population. Japan continues to lead the percentage of the population older than 65 years (28%) [1]. Furthermore, the average life span of Japanese people has considerably increased in recent years. However, healthy life expectancy is shorter than overall life expectancy. The timespan from healthy life to death is approximately 10 years [2]. In Japan, the number of people who require long-term care is on the rise. In 2011, 3.783 million people needed long-term care, whereas in 2016, the number increased to 4.459 million [2]. To address this issue, it is vital to take measures that can extend the healthy life expectancy of people.

Amongst the various reasons for long-term care, the locomotor disorder is a major one, accounting for 22.7% in 2016 [2]. In 2007, the Japanese Orthopedic Association proposed the concept of ‘locomotive syndrome’ (Locomo), wherein a decline in mobility functions such as sit-to-stand or gait decline, was observed due to an impairment of locomotive organs [3]. To improve and sustain standing and gait functions, a method of locomotion training, called ‘Locotra,’ has been recommended [3]. This training consists of exercises such as standing on one leg with eyes open and squatting. The beneficial effects of these exercises have been reported by other researchers [4, 5]. Although Locotra is safe and feasible to practice at home, the location where instructions should be provided, and subsequent follow-up has not been decided upon.

Considering the rising medical costs in Japan, it is important to prevent lifestyle-related diseases. To address this issue, the health support pharmacy system was introduced in 2016 in Japan [6–10]. The role of a pharmacy is to help the community to improve its health. However, the new services leave the contents up to each pharmacy. Pharmacies have the following three advantages: a pharmacist and a medical specialist are always present at the pharmacy, stores are present at regular intervals, and people can easily access pharmacies when compared to hospitals. We considered the possibility of establishing a new pharmacy health support by exploiting these advantages. Hence, it is the responsibility of the pharmacists to decide which service is needed and how to provide the new service.

The purpose of this study was to examine the effect of pharmacists’ instructions and follow-up of Locotra in their community, as the health support pharmacy system. We evaluated pharmacist instructions and conducted a follow-up of Locotra in citizens of the community and tested the effects of Locotra at pharmacies.

Methods

Training pharmacists

The study was conducted at pharmacies in Aichi Prefecture and western Shizuoka Prefecture that consented to participate in this study. Before conducting the study, the pharmacists were trained to acquire sufficient knowledge and skills about Locomo and Locotra from the Care Prevention Network Association, an organization that promotes Locotra. The contents of the training were as follows: epidemiology, pathophysiology, Locomo degree judgement method, and locomotion training instruction method.

Participants

Locomo clinical decision limits were established in two stages. The beginning of the decline in mobility functions was categorized as stage 1, and a progression in mobility function decline was categorized as stage 2 [4]. The participants of this study were those with Locomo stage 1. Pharmacy visitors were recruited as participants for this study. A pharmacy visitor was any local resident who visited a pharmacy (with or without a prescription) to buy medicine, for consultation, or for any other reason. Considering the rising medical costs in Japan, it is important to prevent lifestyle-related diseases. To address this issue, the health support pharmacy system was introduced in 2016 in Japan [6–10]. The role of a pharmacy is to help the community to improve its health. However, the new services leave the contents up to each pharmacy. Pharmacies have the following three advantages: a pharmacist and a medical specialist are always present at the pharmacy, stores are present at regular intervals, and people can easily access pharmacies when compared to hospitals. We considered the possibility of establishing a new pharmacy health support by exploiting these advantages. Hence, it is the responsibility of the pharmacists to decide which service is needed and how to provide the new service.

The purpose of this study was to examine the effect of pharmacists’ instructions and follow-up of Locotra in their community, as the health support pharmacy system. We evaluated pharmacist instructions and conducted a follow-up of Locotra in citizens of the community and tested the effects of Locotra at pharmacies.

Observation period

The observation period was 28 ± 7 days from the pre-intervention assessment date. During the observation period, we examined the registered participants with respect to the number of visits to the pharmacy, guidance contents about health at the pharmacy, and their health status.

Clinical decision limits were established in two stages (Table 1). The following criteria were used to indicate the beginning of a decline in mobility functions and the participant was categorized as stage 1 if any of the following three conditions were met: stand-up test score ≥
checked that the participant was performing Locotra following the correct procedure. The pharmacist consultation was at the discretion of the pharmacist. When the participant visited the pharmacy, the pharmacist made an appointment for the next available day. The study was completed on the third visit.

**Statistical analysis**

Changes in measurements due to the intervention were compared to the baseline and analysed with Wilcoxon’s signed-rank test. A correlation analysis between changes in parameters and frequency of Locotra was conducted with Spearman’s rank correlation coefficient. A statistical significance threshold of 5% was used \((p < 0.05)\). All statistical analyses were carried out using IBM SPSS Statistics for Windows, Version 26 (IBM Corp., Armonk, NY, USA).

### Results

Informed consent was obtained from 16 people, of which 12 (who met the selection criteria) were registered in the study. Twelve participants completed the study, but only 11 were included in the analysis because one participant deviated from the protocol (the first monthly inspection interval was 27 days, which was shorter than the default 28 days or more). The baseline characteristics of the participants are presented in Table 2.

The implementation rates of Locotra are presented in Table 3. The results of the single-leg standing test (with the eyes open) and squatting test were similar. At least once a day, the lowest percentage of implementation was 78% throughout the study. Similar results were observed for squats.

Table 4 presents the changes in the locomotive syndrome-related test results. After 3 months, the score of 25-question GLFS decreased significantly. In addition, leg muscle strength and standing time on one leg, with the eyes open increased. Consequently, three participants were no longer in Locomo stage 1. Furthermore, to verify the correlation between these values and the implementation rate, we performed Spearman’s rank correlation coefficient. As shown in Table 5, the 25-question GLFS and left leg muscle strength correlated with the implementation percentage of days for single-leg standing with the eyes open. However, no correlation was observed with the number of times nor days of locomotive training.

An increase in the number of visits to the pharmacy was reported in four out of eleven participants. At the start of the study, pharmacists provided consultation to one participant. However, by the end of the study, nine participants received consultation by the pharmacists. While consultation regarding Locomo was most frequently provided \((n = 10)\), consultations regarding cold,

### Table 1 Locomotive syndrome clinical decision limits

|                      | Stage 1               | Stage 2               |
|----------------------|-----------------------|-----------------------|
| Stand-up test score  | ≥ 3 and < 5           | < 3                   |
| Two-step test score  | ≥ 1.1 and < 1.3       | < 1.1                 |
| 25-question GLFS     | ≥ 7 and < 16          | 2 ± 17                |

Stand-up test score is expressed as the height of the lowest stool from which the subject was able to stand-up; all failed = 0, 40 cm with both legs = 1, 30 cm with both legs = 2, 20 cm with both legs = 3, 10 cm with both legs = 4, 40 cm with a single-leg = 5, 30 cm with a single-leg = 6, 20 cm with a single-leg = 7, and 10 cm with a single-leg = 8. Two-step test score was calculated by normalising the maximal length of two steps taken by the participant by his/her height; 25-question GLFS 25-question geriatric locomotive function scale.
skin, blood glucose, stress, light-headedness, health foods, and family health (each, \( n = 1 \)) were also provided. The purchase of over the counter drugs was reported in two participants. Information on the health status, ascertained by the pharmacist, was reported for all 11 participants, while information on body pain, medical history, and weight fluctuation was obtained from 11, 5, and 2 participants, respectively.

**Discussion**

In this study, we demonstrated that a pharmacy could act as a health support system and provide instructions and follow-up to the community regarding Locotra. Several studies have documented the effectiveness of Locotra. For example, three locomotion training sessions were conducted for elderly home-dwelling people, and the results for the 25-question GLFS, stand-up test, and two-step test improved for those who attended all three sessions compared with those who were absent for more than one session [4]. In another study, it was reported that the results of the one leg standing test and sit-to-stand test were improved by home-visit locomotion training, with telephone support, for elderly people who were not attending any preventive-care program [5]. However, a suitable location for the dissemination of Locotra instructions and follow-up has not been established. In this study, we successfully demonstrated that a pharmacy is a suitable place to provide instructions for Locotra and subsequent follow-up.

Adherence to Locotra is usually difficult. It has been reported that without intervention, 40% of people do not use Locotra 2 years after the administration of the training [17]. However, following-up with the participants via telephone once every 2 weeks reduced the number of people who did not perform Locotra to 14.9% [18]. In this study, the elderly participants were instructed at the pharmacies and followed up regarding Locotra once a month for 3 months. Results showed that all 11 individuals were able to continue Locotra until the end of the observation period, with a Locotra implementation percentage of at least 78%. In addition, it was noted that the elderly participants could continue Locotra safely during the study. Consequently, the results of the 25-question GLFS, straight leg raising test, and standing time on one leg improved overtime. These findings were consistent with those of a previous study [4]. It should be noted that the effect of Locotra was positively correlated with

### Table 2 Baseline Characteristics of Participants

| Characteristic                  | Participants (\( n = 11 \)) |
|--------------------------------|-----------------------------|
| Median age, years (range)       | 74 (68–82)                  |
| Sex                            |                             |
| Male / Female                   | 4 / 7                       |
| Family unit                     |                             |
| Single / Couple / Other         | 3 / 2 / 6                   |
| Disease                        |                             |
| Hypertension / Diabetes / Hernia / Prostatic hyperplasia / None | 5 / 2 / 1 / 1 / 2 |
| Social engagement               |                             |
| Yes / No                       | 9 / 2                       |
| Outdoor activity, median number of days in a month (range) | 30 (12–30) |
| Sleeping on                     |                             |
| Futon / Bed                    | 7 / 4                       |
| Household activities            |                             |
| Yes / No                       | 11 / 0                      |

### Table 3 Implementation Percentage of Locomotion Training

|                       | 1st month | 2nd month | 3rd month | Total |
|-----------------------|-----------|-----------|-----------|-------|
|                       |         | \( n = 11 \) |         | \( n = 11 \) |         | \( n = 11 \) |         | \( n = 11 \) |         |
|                       | Median (range) | Median (range) | Median (range) | Median (range) | Median (range) | Median (range) | Median (range) | Median (range) |
| Frequency of single-leg standing with the eyes open |          |           |           |        |          |           |           |        |
| None                  | 3 (0–38) | 0 (0–19)  | 0 (0–41)  | 7 (0–22) |
| One time a day        | 9 (0–74) | 7 (0–82)  | 7 (0–93)  | 10 (0–82) |
| Two times a day       | 24 (0–84)| 46 (0–89)| 54 (0–82)| 38 (0–81) |
| Three times a day     | 43 (0–100)| 39 (0–100)| 29 (0–100)| 46 (0–100) |
| At least one time a day | 97 (63–100)| 100 (81–100)| 100 (59–100)| 93 (78–100) |
| Frequency of squats   |          |           |           |        |          |           |           |        |
| None                  | 3 (0–38) | 0 (0–19)  | 0 (0–41)  | 7 (0–22) |
| One time a day        | 6 (0–74) | 5 (0–82)  | 7 (0–93)  | 10 (0–82) |
| Two times a day       | 24 (0–84)| 46 (0–89)| 54 (0–82)| 38 (0–81) |
| Three times a day     | 43 (0–100)| 39 (0–100)| 29 (0–100)| 46 (0–100) |
| At least one time a day | 97 (63–100)| 100 (81–100)| 100 (59–100)| 93 (78–100) |
the implementation percentage of days of Locotra and not the number of Locotra exercises. Previous studies have indicated no change in the muscle function with three sets and one set of the same exercise per day [19]. It is important to educate the participants to continue practicing Locotra without trying too hard. The pharmacist can play the role of an escort runner to prevent Locomo by regularly measuring the Locomo degree and providing guidance and follow-up to Locotra for the elderly people.

The effects of other health support services have also been reported [6–10]. In the UK, Healthy Living Pharmacies has been providing these services since 2009 [20]. Furthermore, Locotra has increased the number of consultations at pharmacies. Hence, Locotra improves communication between the community and pharmacists. Our results suggest that instruction and follow-up of Locotra at pharmacies might be a novel effective service as a part of a health support pharmacy system.

Notably, this study had some limitations. The number of participants in this study was small. In addition, this study was performed without a control group. The differences in the teaching ability of pharmacists could not be analyzed. Nutrition and diet of the participants was not considered. We did not analyze the differences with respect to gender, age group, and family structure of the

### Table 4 Changes in the Locomotive Syndrome-Related Test

|                              | Baseline | 1 month | 2 months | 3 months | Baseline vs. 3 months p-value |
|------------------------------|----------|---------|----------|----------|-----------------------------|
| Stand-up test (n = 11)       | 3 (3–5)  | 3 (3–5) | 3 (3–5)  | 4 (3–5)  | 0.083                       |
| Two-step test (n = 11)       | 1.4 (1.1–1.8) | 1.4 (1.2–1.7) | 1.4 (1.2–1.7) | 1.3 (1.2–1.7) | 0.739                       |
| 25-question GLFS (n = 11)    | 6 (1–12) | 3 (0–12) | 2 (0–8)  | 1 (0–7)  | 0.014                       |
| No locomotive syndrome (n)   | 0        | 1       | 2        | 3        | –                           |
| Leg muscle strength (n = 8)  |          |         |          |          |                             |
| Right leg (Newton)           | 322.5    | 389     | 403      | 391      | 0.025                       |
| Median (range)               | (187–429)| (173–471)| (197–493)| (239–521)|                             |
| Left leg (Newton)            | 361      | 363     | 424.5    | 399      | 0.025                       |
| Median (range)               | (238–519)| (216–508)| (259–559)| (257–584)|                             |
| Standing time on one leg with the eyes open (n = 11) |          |         |          |          |                             |
| Right leg [s] Median (range) | 40 (12–60)| 58 (10–60)| 60 (7–60)| 47 (20–60)| 0.044                       |
| Left leg [s] Median (range)  | 40 (3–60)| 60 (20–60)| 60 (20–60)| 60 (15–60)| 0.021                       |
| SF-8™ Health Survey (n = 11) |          |         |          |          |                             |
| PCS Median (range)           | 53 (42–56)| 52 (44–59)| 5 (42–58)| 54 (46–58)| 0.374                       |
| MCS Median (range)           | 52 (43–57)| 54 (45–57)| 54 (42–56)| 52 (46–56)| 0.859                       |

25-question GLFS 25-question geriatric locomotive function scale, PCS physical component summary, MCS mental component summary

### Table 5 Correlations between Changes in Parameters and Frequency of Locomotion Training

|                              | Single-leg standing with the eyes open | Squats |
|------------------------------|---------------------------------------|--------|
|                             | Number of times | Number of days | Implementation percentage of days | Number of times | Number of days | Implementation percentage of days |
| 25-question GLFS (n = 11)    | −0.235         | −0.457         | −0.640*                      | −0.235         | −0.457         | −0.640*                      |
| Leg muscle strength (n = 8)  |          |                |                              | −0.167         | −0.390         | −0.386                      |
| Right leg                   | −0.024        | 0.561          | 0.747*                       | −0.024         | 0.561          | 0.747*                       |
| Left leg                    | −0.187        | −0.080         | −0.280                       | −0.187         | −0.080         | −0.280                       |
| Standing time on one leg with the eyes open (n = 11) |          |                |                              | 0.193          | 0.413          | 0.451                       |

Values are expressed as Spearman’s rank correlation coefficient (p-value) for nonparametric variables. *p < 0.05. 25-question GLFS 25-question geriatric locomotive function scale
participants. Thus, in future, it is necessary that the effects of continuous locomotion training should be investigated based on the characteristics of the participants. Furthermore, the results require validation in a larger comparative study. Nevertheless, the results from this study clearly indicated that Locotra may be applied at pharmacies, and thereby extend the healthy life expectancy of citizens.

Conclusions
Pharmacists provided locomotive training instructions to elderly people at the pharmacy. The elderly were able to continue locomotive training for 3 months. Improvements were observed in 25-question GLFS, muscle strength, and standing time on one leg. Thus, continuous locomotion training provided at the pharmacies could contribute to the prevention of locomotive syndrome.

Abbreviations
Locomo: Locomotive syndrome; 25-question GLFS: 25-question Geriatric Locomotive Function Scale; UMIN-CTR: University hospital Medical Information Network Clinical Trials Registry

Acknowledgements
We would like to thank all the study participants. We would also like to acknowledge the contribution by the research assistant, Ms. Akane Sekiya. We would like to thank Mr. Masanori Takahara, Mr. Akinori Miyata, and Dr. Shigeki Miyata for providing their assistance in pharmacist training. Finally, we would like to express our deep gratitude to Mr. Norimasa Umemura, Mr. Takui Yamazaki, and Mr. Masaharu Takao for their cooperation in conducting the research at the pharmacies.

Authors’ contributions
All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by CK, KY, MK, HA, RN, YO, JN, SM, AH, and TS. The first draft of the manuscript was written by CK, and all authors commented on different versions of the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by a Grant in Aid for Research at Nagoya City University and a grant from OTC Self-Medication Promotion Foundation. Furthermore, a part of this work was supported by JSPS KAKENHI Grant Number JP18K06754.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
Written informed consent was obtained from all participants. All procedures followed were in accordance with the ethical standards of the Nagoya City University Hospital Clinical Research Review Board (Nagoya City University Graduate School of Medical Science; date of approval: 23 May 2017; approval number: 46-17-0001), and with the Declaration of Helsinki (1964 and later versions). This study was registered with the University hospital Medical Information Network Clinical Trials Registry (UMIN-CTR; identification No. UMIN000027963. Registered: 28 June 2017, https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000052034).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizo-ku, Nagoya 467-8603, Japan. 2Educational Research Centre for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizo-ku, Nagoya 467-8603, Japan. 3Department of Medical Education, Graduate School of Medicine, Nagoya City University, 1 Kawasumi, Mizo-ku, Nagoya 467-8603, Japan. 4Asai Pharmacy Tachibana Branch, 6-24-1 Tachibana-cho, Tsumi, Aichi 496-0038, Japan. 5Haruka Pharmacy Sakoh, 2-5-11 Sakoh, Nishi-ku, Nagoya 451-0852, Japan. 6Yamazaki Pharmacy Kamiyama Branch, 2-11-10 Kamiyama, Naka-ku, Hamamatsu 433-8122, Japan. 7Kyowa Pharmacy Kariya Ekimae Branch, 1-58-102 Minamikariya-cho, Kariya, Aichi 448-0841, Japan. 8Shoiedo Pharmacy, 1-48-101 Yutaka, Minami-ku, Nagoya 457-0863, Japan. 9Olive Pharmacy Asada Branch, 302 Nishimaeda, Asada-cho, Nishin, Aichi 470-0124, Japan.

Received: 17 July 2020 Accepted: 11 November 2020
Published online: 23 November 2020

References
1. United Nations. World population prospects 2019: Data booklet. 2019. https://population.un.org/wpp/Publications/Files/WPP2019_DataBooklet.pdf. Accessed 16 July 2020.
2. Cabinet Office Japan. Annual report on the ageing society [Summary] FY 2019. 2019. https://www8.cao.go.jp/kourei/english/annualreport/2019/pdf/2019.pdf. Accessed 16 July 2020.
3. Nakamura K, Ogata T. Locomotive syndrome: definition and management. Clin Rev Bone Miner Metab. 2016;14:56–67.
4. Kata M, Morishii M, Hazama A, Hiramoto K. Assessment of the effects of a group intervention program used in home-dwelling elderly individuals to promote home exercise and prevent locomotive syndrome. J Phys Ther Sci. 2019;31:470–4.
5. Ito S, Hashimoto M, Aduma S, Yasumura S. Effectiveness of locomotion training in a home visit preventive care project: one-group pre-intervention versus post-intervention design study. J Orthop Sci. 2015;20:1078–84.
6. Um IS, Krass I, Armour C, Gill T, Chara BB. Developing and testing evidence-based weight management in Australian pharmacies: a healthier life program. Int J Clin Pharm. 2015;37:822–33.
7. Fujita N, Nabatani N, Umemura N, Kikuchi C, Suzuki T. Lifestyle improvement through continuous measurements of hemoglobin A1c levels and lifestyle checks at the community pharmacy in three cases. Yakugaku Zasshi. 2016;136:1445–8.
8. Wada Y, Wada Y, Ennyu S, Shimokawa K, Ishii F. Ability of community pharmacists to promote self-care and self-medication by local residents [I]: improvements in bone mineral density. Drug Discov Ther. 2017;11:35–40.
9. Hirota N, Inagaki M, Matsumura N, Utsunomiya R. An outcome evaluation of the health support pharmacy efforts to improve health literacy. Jpn J Pharm Health Care Sci. 2018;44:244–50.
10. Suzuki R, Suzuki T, Kikuchi C. Improvements in lifestyle from a lifestyle consecutive self-review at a pharmacy. Yakugaku Zasshi. 2019;139:1047–54.
11. Omori G, Koga Y, Watanabe H, Tanioka M, Nawata A, Narumi K, et al. Quadriceps muscle strength and its relationship to radiographic knee osteoarthritis in Japanese elderly. J Orthop Sci. 2013;18:536–42.
12. Ohka J, Seki M, Ao M, Okajima R, Kikuma A, Takaoka H, Aoyama K, Tanaka K. Comparison of lower leg muscle strength and grip strength for diagnosing slower gait speed in the elderly. Osteoporos Sarcopenia. 2017;3:128–31.
13. Seichi A, Hoshino Y, Doi T, Aki M, Tobimatsu Y, Kita K, Iwaya T. Determination of the optimal cutoff time to use when screening elderly people for locomotive syndrome using the one-leg standing test (with eyes open). J Orthop Sci. 2014;19:620–6.
14. Fukushima S, Suzukamo Y. Manual of the SF-8 Japanese version. Kyoto: iHope International Corporation; 2004.
15. Turner-Bowker DM, Bayliss MS, Ware JE, Kosinski M. Usefulness of the SF-8 health survey for comparing the impact of migraine and other conditions. Qual Life Res. 2003;12:1003–12.
16. Tokuda Y, Okubo T, Ohde S, Jacobs J, Takahashi O, Omata F, Yanai H, Hinohara S, Fukui T. Assessing items on the SF-8 Japanese version for health-related quality of life: a psychometric analysis based on the nominal categories model of item response theory. Value Health. 2009;12:658–73.
17. Arai T, Fujita H, Maruya K, Asahi R, Morita Y, Ishibashi H. Follow-up questionnaire survey about exercise adherence after the "locomotion training workshop". J Jpn Osteoporosis Soc. 2018;4:171–6.

18. Arai T, Fujita H, Maruya K, Yoshizawa S, Asahi R, Morita Y, et al. The investigation of improvement effect on physical function and its sustainability after 6 month by "LOCOMO CALL" program as municipal nursing care prevention project. J Jpn Osteoporosis Soc. 2018;4:531–40.

19. Radaelli R, Brusco CM, Lopez P, Rech A, Machado CLF, Graziani R, Muller DC, Tufano JJ, Cadore EL, Pinto RS. Muscle quality and functionality in older women improve similarly with muscle power training using one or three sets. Exp Gerontol. 2019;128:110745.

20. Brown D, Portlock J, Rutter P, Nazar Z. From community pharmacy to healthy living pharmacy: positive early experiences from Portsmouth, England. Res Social Adm Pharm. 2014;10:72–87.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.